Jan 11, 2022 / 08:00PM GMT
Anupam Rama - JPMorgan Chase & Co, Research Division - VP and Analyst
Welcome, everybody, to the 40th Annual JPMorgan Healthcare Conference. My name is Anupam Rama. I'm one of the senior biotech analyst here at JPMorgan. I'm joined by [Malcolm Kuno], Priyanka Grover and Caleb Smith from the team. Our next presenting company is ORIC, and presenting on behalf of the company, we have CEO, Jacob Chacko. (Operator Instructions) With that, Jacob, take it away.
Jacob M. Chacko - ORIC Pharmaceuticals, Inc. - President, CEO & Director
Thanks, Anupam. Thanks for having us. It's our pleasure to talk to you today about ORIC Pharmaceuticals. We've only got, I think, about 20 minutes to go through quite a bit of information in the slide, so I'm going to go at a decent clip and then, Anupam, make sure to save enough time for Q&A at the end.
So Slide 2, just walk through some of the standard forward-looking statements, but let's jump right into the presentation on Slide 3. And this in one slide I think encapsulates why we were so excited about what we're
Oric Pharmaceuticals Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot